In one case study regarding breast cancer treatment, MOLI used pan-drug datasets targeted at the epidermal growth factor receptor (EGFR) pathway for breast, lung, kidney and prostate cancers and discovered that cetuximab and erlotinib may be useful for treating breast cancer [43]. The gene discussed is EGFR; the disease is prostate cancer.